BioVie
Manufacturing · Nevada, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
680 W Nye Ln Ste 201, Carson City, Nevad...Phone Number
(775) 888-3162Website
www.bioviepharma.comRevenue
-Stock Symbol
BIVIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. Headquartered in Carson City, Nevada, the company focuses on its lead drug candidate bezisterim, which inhibits the production of tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance – both of which are drivers of Alzheimer's and Parkinson's. The company also develops BIV201, which is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.Explore more
BioVie Org Chart
JP
Chief Medical Officer & Executive VP, Researc...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioVie your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BioVie recently announced quarterly report
BioVie, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if BioVie is spiking on competitors!
Funding: Get notified immidiatlly once BioVie has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioVie
Click to see if BioVie had a recent Job posting/layoffs
Product Launch: Get notified when BioVie launches new products
Check if BioVie has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to BioVie
Compare insights from companies similar to BioVie, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioVie is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioVie is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioVie.
BioVie financials insights
Gather financial insights about BioVie, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$16M
2024
Private Equity
$18.8M
Grant
$12.6M
BioVie Tech Stack
A closer look at the technologies used by BioVie
Most Recent Scoops
Person-Based
Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
BioVie News & Media
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Last Patient Last On-Site Visit Completed with Topline Data Release Targeted September 2026 Last Patient Last On-Site Visit Completed with Topline Data Release Targeted September 2026BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures.Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioVie
Sign Up For FreeTo access detailed company insights
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. Headquartered in Carson City, Nevada, the company focuses on its lead drug candidate bezisterim, which inh... Read More
